Syndax to Participate in the BTIG Biotechnology Conference

August 5, 2019
PDF Version

WALTHAM, Mass., Aug. 5, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will participate in a panel discussion on targeted oncology therapies at the BTIG Biotechnology Conference on Monday, August 12, 2019 at 4:00 p.m. ET at the St. Regis New York.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's lead product candidate, entinostat, a once-weekly, oral, small molecule, class I HDAC inhibitor, is being tested in a phase 3 combination trial with exemestane for treatment of advanced HR+, HER2- breast cancer and has been evaluated in combination with several approved PD-1/PD-(L)1 antagonists. The Company's pipeline also includes SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.

Syndax Contacts

Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902

Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com
Tel 212.600.1902

SNDX-G

Cision View original content:http://www.prnewswire.com/news-releases/syndax-to-participate-in-the-btig-biotechnology-conference-300895926.html

SOURCE Syndax Pharmaceuticals, Inc.